SGLT 2 Inhibitors and Hypertension: Mild but Effective. What can we expect ?

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of medications used for the treatment of diabetes mellitus (DM). It has been shown that, in addition to a favorable metabolic effect, they significantly reduce atherosclerotic events, cardiovascular and total mortality, hospitalization duration in patients with heart failure and have a significant effect on reducing the progression of chronic kidney disease. It has been observed that in patients with diabetes mellitus, they lead to a reduction of blood pressure (BP). The aim of this article is to evaluate current knowledge about mechanisms of antihypertensive action and clinical benefits of SGLT2 inhibitors in reducing arterial blood pressure in patients with diabetes mellitus and arterial hypertension.